Dashi Pharmaceutical

Dashi Pharmaceutical is a clinical-stage biopharmaceutical company based in China, focused on the discovery and development of innovative small molecule therapeutics for oncology and autoimmune diseases. The company's lead candidate, DS-200, is a novel androgen receptor antagonist currently being evaluated in Phase 2 clinical trials for the treatment of metastatic castration-resistant prostate cancer. Dashi Pharmaceutical leverages its expertise in medicinal chemistry to develop high-potency compounds with improved safety profiles compared to existing standards of care. The company aims to address significant unmet medical needs in the Chinese and global markets through targeted drug design.